Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:14:59 EDT Thu 10 Oct 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:OCS - OCULIS HOLDING AG - https://investors.oculis.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OCS - Q0.114.60·17.360.115.20    15.49  9.05Oct 09Oct 0215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-02 04:00U:OCSNews ReleaseOculis Announces Appointment of Daniel S. Char as Chief Legal Officer
2024-09-19 13:00U:OCSNews ReleaseOculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
2024-08-29 04:00U:OCSNews ReleaseOculis to Present at Upcoming September Investor Conferences
2024-08-27 04:00U:OCSNews ReleaseOculis Reports Q2 2024 Financial Results and Provides Recent Company Update
2024-08-15 08:00U:OCSNews ReleaseOculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
2024-07-30 16:10U:OCSNews ReleaseOculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
2024-06-27 06:31U:OCSNews ReleaseOculis and EURETINA Announces the Ramin Tadayoni Award
2024-06-10 05:00U:OCSNews ReleaseOculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
2024-05-30 04:00U:OCSNews ReleaseOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
2024-05-08 16:10U:OCSNews ReleaseOculis Reports Q1 2024 Financial Results and Provides Company Updates
2024-05-08 16:05U:OCSNews ReleaseOculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
2024-05-06 06:30U:OCSNews ReleaseOculis to Present at Bank of America Global Healthcare Conference
2024-04-29 16:05U:OCSNews ReleaseOculis Publishes Invitation to the Annual General Meeting
2024-04-22 09:28U:OCSNews ReleaseOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
2024-04-11 08:55U:OCSNews ReleaseOculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
2024-04-10 06:30U:OCSNews ReleaseOculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
2024-04-08 06:30U:OCSNews ReleasePositive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
2024-04-04 06:30U:OCSNews ReleaseOculis to Participate at Upcoming April Investor Conferences
2024-03-18 06:30U:OCSNews ReleaseOculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
2024-02-28 06:30U:OCSNews ReleaseOculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments